Skip to content
ClinCalc Pro
Menu
Emergency Contraceptive (Progestogen) Pregnancy: Should not be given to pregnant women; it will not interrupt a pregnancy. In the case of continued pregnancy, limited epidemiological data indicate no adverse effects on the fetus, but there are no clinical data on the potential consequences of doses greater than 1.5 mg. Secreted into breast milk - exposure of an infant can be reduced by taking the tablet immediately after a feed and avoiding nursing for at least 8 hours afterwards.

Levonorgestrel (Emergency Contraception)

Brand names: Levonelle 1500, Upostelle, Ezinelle

Levonorgestrel is a progestogen used as emergency contraception after unprotected sex or contraceptive failure. It is effective when taken up to 72 hours afterwards, and the sooner it is taken the more effective it is.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: One tablet (levonorgestrel 1.5 mg) as a single dose
Route: Oral
Frequency: Single dose, taken as soon as possible - preferably within 12 hours and no later than 72 hours after unprotected intercourse
SPC source: Levonorgestrel 1.5mg Tablets. If vomiting occurs within three hours of taking the tablet, another tablet should be taken immediately. ENZYME INDUCERS: women who have used enzyme-inducing drugs during the last 4 weeks and need emergency contraception are recommended to use a non-hormonal emergency contraceptive (i.e. Cu-IUD), or to take a double dose of levonorgestrel (i.e. 2 tablets taken together) if unable or unwilling to use a Cu-IUD. Can be used at any time during the menstrual cycle unless menstrual bleeding is overdue. After use, a local barrier method (condom, diaphragm, spermicide, cervical cap) is recommended until the next menstrual period starts; use does not contraindicate continuation of regular hormonal contraception. Repeated administration within a menstrual cycle is not advisable because of the possibility of cycle disturbance. Treatment following a second act of intercourse in the same cycle, or more than 72 hours after unprotected intercourse, may be ineffective. If menstrual periods are delayed by more than 5 days, or abnormal bleeding occurs at the expected date, or pregnancy is suspected for any other reason, pregnancy should be excluded; consider ectopic pregnancy if pregnancy occurs after treatment. Limited and inconclusive data suggest there may be reduced efficacy with increasing body weight or BMI, but in all women emergency contraception should be taken as soon as possible after unprotected intercourse regardless of body weight or BMI. Emergency contraception is an occasional method and should in no instance replace a regular contraceptive method, and does not replace precautions against sexually transmitted diseases. PAEDIATRIC: 'There is no relevant use of levonorgestrel for children of prepubertal age in the indication emergency contraception.' No weight-based paediatric dose is stated - the single 1.5 mg tablet regimen is the only posology given.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients (§4.3)
  • Not recommended in patients at risk of ectopic pregnancy (previous history of salpingitis or of ectopic pregnancy) (§4.4)
  • Not recommended in patients with severe hepatic dysfunction (§4.4)
  • Contains lactose monohydrate - patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine (§4.4)

Side effects

  • Nausea (very common) - the most commonly reported undesirable effect; lower abdominal pain (very common)
  • Headache (very common); dizziness (common)
  • Bleeding not related to menses (very common) - patterns may be temporarily disturbed but most women will have their next period within 5-7 days of the expected time
  • Delay of menses more than 7 days (very common); irregular menstruation (common)
  • Fatigue (very common); breast tenderness (common); diarrhoea and vomiting (common)

Interactions

  • Enzyme-inducing drugs used within the last 4 weeks - a non-hormonal emergency contraceptive (Cu-IUD) is recommended, or a double dose of levonorgestrel (2 tablets taken together) for women unable or unwilling to use a Cu-IUD (§4.2)
  • Severe malabsorption syndromes such as Crohn's disease might impair the efficacy of levonorgestrel (§4.4)
  • NOTE: SPC §4.5 was truncated in the fetched source ('The metabolism of ...') - the full interactions section still needs to be reviewed

Clinical monograph

How it works

It works mainly by delaying or inhibiting ovulation; it is not an abortifacient and does not disrupt an established pregnancy.

Prescribing in practice

  • It does not provide ongoing contraception for the rest of the cycle, so reliable contraception must be continued or started.
  • A larger dose or an alternative (ulipristal acetate or a copper intrauterine device) may be advised at higher body weight or after enzyme-inducing drugs.
  • It can be used more than once in a cycle if needed, but a copper intrauterine device is the most effective emergency option.

Monitoring

No routine monitoring is required; advise a pregnancy test if the next period is more than a few days late or is unusually light, and arrange ongoing contraception.

Counselling the patient

  • Take it as soon as you can after unprotected sex, as it works better the earlier it is taken.
  • If you vomit within a couple of hours of the dose, seek advice as you may need to repeat it.
  • Use condoms or abstain until you start or restart reliable contraception, and do a pregnancy test if your period is late.

Evidence & guidelines

Recommended emergency contraceptive option (FSRH; NICE CKS).

Reference: FSRH Emergency Contraception Guideline 2017 (updated 2023); NICE; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.